C2 PHARMA Receives CEP approval for Oxybuprocaine Hydrochloride Posted on 28. January 202528. January 2025 by admin_c2p
C2 PHARMA Marks 10th Year Anniversary Attendance at CPhI Milan with Expanded Ophthalmic API Portfolio Posted on 24. September 202424. September 2024 by admin_c2p
C2 PHARMA EXPANDS OPHTHALMIC API PORTFOLIO WITH NAPHAZOLINE HYDROCHLORIDE LAUNCH Posted on 12. September 2024 by admin_c2p
C2 PHARMA’s Upcoming Launch of Oxybuprocaine Hydrochloride Posted on 6. March 20246. March 2024 by admin_c2p
C2 PHARMA x PharmaSource Ophthalmics Buyer Guide Posted on 15. February 202415. February 2024 by admin_c2p
C2 PHARMA Receives DMF Approval in China for Pilocarpine Nitrate Posted on 21. November 202322. November 2023 by admin_c2p
Manufacturing Chemist StandSide interview with C2 PHARMA’s CEO at CPHI WW Barcelona Posted on 7. November 20237. November 2023 by admin_c2p
Optimizing the Total Cost of Ownership by C2 PHARMA’s CEO, Andrew Badrot Posted on 30. October 202330. October 2023 by admin_c2p
Senior Manager Business Development, Serge Tarabay PharmaSource Podcast Interview Posted on 18. October 202318. October 2023 by admin_c2p
C2 PHARMA Expands API Portfolio with Global Regulatory Access Ahead of CPhI Barcelona Posted on 17. October 202317. October 2023 by admin_c2p
Head of Quality, Tara Fitzpatrick Interviews with Pharma Techs Felicity Thomas Posted on 2. October 2023 by admin_c2p
EDQM Grants C2 PHARMA CEP Approval for Commercial Sale of Cyclopentolate Hydrochloride Posted on 27. June 202327. June 2023 by admin_c2p
C2 PHARMA Receives Approval for Digoxin China DMF, Becoming China’s Only European Supplier of This API Posted on 13. June 202327. June 2023 by admin_c2p